Lundbeck bets on four core products during hard year
While Northera sales plummeted more rapidly than expected, Lundbeck plans for its other products to make up for this loss, especially now that the migraine drug Vyepti is gaining momentum.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
On Tuesday, Lundbeck brought a pleasant surprise to the market by presenting its report for Q1 which was better than anticipated, both in terms of the bottom line and the top line.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck loses top-line terrain but surpasses expectations
For subscribers
Lundbeck: Pandemic and currency woes have led to setbacks
For subscribers
.jpg&w=384&q=75)
